Vaccine against rsv

Abstract

Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid molecule encoding a RSV F protein or immunologically active part thereof.

1 . A composition for vaccinating a subject against respiratory syncytial virus (RSV) F protein, composition comprising:
 a recombinant human adenovirus of serotype 26 that comprises a nucleic acid molecule encoding an RSV F protein or a fragment of an RSV F protein,   which composition, upon a single intramuscular injection to a Cotton rat ( Sigmodon hispidus ), gives complete protection against RSV challenge replication in a Cotton rat model of respiratory viral infection.   
     
     
         2 . The composition of  claim 1 , wherein the nucleic acid molecule encodes a peptide comprising SEQ ID NO: 1. 
     
     
         3 . The composition of  claim 1 , wherein the nucleic acid molecule encoding RSV F protein has been codon optimized for expression in a human cell. 
     
     
         4 . (canceled) 
     
     
         5 . The composition of  claim 1 , wherein the recombinant human adenovirus has:
 a deletion in the E1 region of the adenoviral genome,   a deletion in the E3 region of the adenoviral genome, or   a deletion in each of the E1 and the E3 regions of the adenoviral genome.   
     
     
         6 . The composition of  claim 1 , wherein the recombinant adenovirus has a genome comprising, at its 5′ end, CTATCTAT. 
     
     
         7 . A method for vaccinating a subject against respiratory syncytial virus (RSV), the method comprising:
 administering to the subject the composition of  claim 1 .   
     
     
         8 . The method according to  claim 7 , wherein the composition is administered to the subject intramuscularly. 
     
     
         9 . The method according to  claim 7 , wherein the composition is administered to the subject in a single administration. 
     
     
         10 . The method according to  claim 7 , further comprising:
 administering to the subject recombinant human adenovirus of serotype 35 that comprises a nucleic acid encoding an RSV F protein or fragment thereof.   
     
     
         11 . A method of immunizing a subject against respiratory synctial virus (RSV), the method comprising:
 intramuscularly administering the composition of  claim 1  to the subject in a single administration.   
     
     
         12 . The method according to  claim 7 , further comprising:
 administering RSV F protein to the subject.   
     
     
         13 . A method for reducing infection and/or replication of respiratory syncytial virus (RSV) in a subject, the method comprising:
 administering to the subject, by intramuscular injection, a composition comprising a recombinant human adenovirus of serotype 26 comprising a nucleic acid molecule encoding a respiratory syncytial virus (RSV) F protein or fragment thereof,   which composition, upon a single intramuscular injection, gives complete protection against RSV challenge replication in a Cotton rat ( Sigmodon hispidus ) model of respiratory viral infection.   
     
     
         14 . A host cell comprising:
 a recombinant human adenovirus of serotype 26 comprising a nucleic acid molecule encoding a respiratory syncytial virus (RSV) F protein or fragment thereof,   which recombinant human adenovirus upon a single intramuscular injection to a Cotton rat ( Sigmodon hispidus ), gives complete protection against RSV challenge replication in a Cotton rat ( S. hispidus ) model of respiratory viral infection.   
     
     
         15 . A process for producing the composition of  claim 1 , the process comprising:
 providing a recombinant human adenovirus of serotype 26 that comprises a polynucleotide encoding an RSV F protein or fragment thereof,   propagating the recombinant human adenovirus in a culture of host cells,   isolating and purifying the recombinant human adenovirus therefrom, and   formulating the purified recombinant human adenovirus to form the composition.   
     
     
         16 . A polynucleotide encoding a recombinant human adenovirus of serotype 26 that comprises a nucleic acid molecule encoding a respiratory syncytial virus (RSV) F protein or a fragment thereof,
 wherein the recombinant human adenovirus after being expressed from said polynucleotide, upon a single intramuscular injection to a Cotton rat ( Sigmodon hispidus ), gives complete protection against RSV challenge replication in a Cotton rat ( S. hispidus ) model of respiratory viral infection.   
     
     
         17 . The method according to  claim 11 , further comprising:
 administering to the subject recombinant human adenovirus of serotype 35 that comprises a nucleic acid molecule encoding an RSV F protein or fragment thereof.   
     
     
         18 . The method according to  claim 8 , wherein the composition is administered to the subject in a single administration. 
     
     
         19 . The method according to  claim 18 , further comprising:
 administering to the subject recombinant human adenovirus of serotype 35 that comprises a nucleic acid encoding an RSV F protein or fragment thereof.   
     
     
         20 . The method according to  claim 8 , further comprising:
 administering RSV F protein to the subject.   
     
     
         21 . The method according to  claim 9 , further comprising:
 administering RSV F protein to the subject.